DRI Capital To Pursue Phase III Assets With Some Of Its Third Royalty Fund
This article was originally published in The Pink Sheet Daily
Toronto-based health care royalty acquirer raises a $1.45 billion third fund, which it says should last between three-and-a-half and five years. It is mainly sticking with its prior investment strategy, although for the first time DRI will look at acquiring royalty rights to promising Phase III candidates.
You may also be interested in...
As survey respondents broadly expect venture capital activity to wane in the coming years, are Google and their like pointing to the next way of financing life sciences innovation? Plus news on recent financings by Civitas Therapeutics, DRI Capital, Five Prime Therapeutics and Cubist Pharmaceuticals.
As the royalty field grows more crowded, the health care investor is turning away from passive royalties, the core strategy of its first fund, to become a lender to companies with products on the market or already approved.
Keeping Track: StrataGraft Continues US FDA’s Biologic Center Approvals Streak; Another CRL For Avenue’s Tramadol IV
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.